GHRH analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
The PIMS instrument was the first to have a deferentially-pumped direct inlet that consists of a stainless steel capillary, followed by a skimmer and conical collimator that focuses the sample into a particle beam that goes on to the ionization region. This type of inlet system is what modern on-line aerosol mass spectrometer instruments use today. In 1982 Sinha and Fredlander developed the particle analysis by mass spectrometry (PAMS), this method was the first to incorporate the optical detection of particles followed by laser desorption/ionization (LDI) in a RTSPMS technique. Prior to this point all RTSPMS methods used surface desorption/ionization (SDI) which consist of a heated metal that ionized the samples. The LDI method involves the sample being hit with a continuous wave, where the particle absorbs photons, and undergoes both desorption and ionization by the same pulse. LDI has several advantages over SDI for on-line single particle mass spectrometry, as such since its development it has been the primary ionization method for RTSPMS. The last major step in RTSPMS development was in 1994 by Kimberly A. Prather. Prather developed the aerosol time-of-flight mass spectrometry (ATOFMS), this method was the first that allow for simultaneous measurement of size and composition of single airborne particle. This techniques was different then previous methods in that instead of using the unreliable method of using light scattering signal intensity to measure particle size, this method uses a two laser system that allows for aerodynamic sizing.
=== Passive systems === When combining a passive daytime radiative cooling system with thermal insulation and evaporative cooling, one study found a 300% increase in ambient cooling power when compared to a stand-alone radiative cooling surface, which could extend the shelf life of food by 40% in humid climates and 200% in desert climates without refrigeration. The system's evaporative cooling layer would require water "re-charges" every 10 days to a month in humid areas and every 4 days in hot and dry areas. A refrigeration system's coefficient of performance (CoP) is an important measure of its performance. It is defined as refrigeration capacity divided by the energy input required to operate the system. While CoP is a simple measure of performance, other measures such as performance factor (PF) are also used in some industrial refrigeration applications. A system's PF relates energy input to refrigeration capacity, and both CoP and PF depend on operating conditions, including temperatures and thermal loads.
== Consumer acceptance == Historically, consumers paid little attention to food technologies. Nowadays, the food production chain is long and complicated and food technologies are diverse. Consequently, consumers are uncertain about the determinants of food quality and find it difficult to understand them. Now, acceptance of food products very often depends on perceived benefits and risks associated with food. Popular views of food processing technologies matter. Especially innovative food processing technologies often are perceived as risky by consumers. Acceptance of the different food technologies varies. While pasteurization is well recognized and accepted, high pressure treatment and even microwaves often are perceived as risky. Studies by the Hightech Europe project found that traditional technologies were well accepted in contrast to innovative technologies. Consumers form their attitude towards innovative food technologies through three main mechanisms: First, through knowledge or beliefs about risks and benefits correlated with the technology; second, through attitudes based on their own experience; and third, through application of higher order values and beliefs. A number of scholars consider the risk-benefit trade-off as one of the main determinants of consumer acceptance, although some researchers place more emphasis on the role of benefit perception (rather than risk) in consumer acceptance.
His season high for strikeouts that year was just seven, achieved in a complete game, four-hit, 4–1 victory over Chicago on September 10. In 30 games (29 starts), he had a 10–14 record, 80 strikeouts, and 91 walks in 189+2⁄3 innings pitched. His 14 losses tied with Bob Friend, Roberts, and Curt Simmons for third in the league (behind Kline's 16 and Johnny Podres's 15), but his 3.42 ERA ranked eighth. Sports Illustrated reported, "Mizell and [Larry] Jackson had impressive ERAs between them but lost more than they won." After working out at the YMCA across from Busch Stadium during the 1958–59 offseason, Mizell showed a stronger fastball in 1959. He did not pitch at the beginning of spring training as he negotiated for a new contract, but he wound up settling for $17,000, his salary each of the previous two seasons. On May 15, he had a season-high 10 strikeouts, allowing just four hits and two unearned runs in an 8–2 victory over the Phillies. He had eight strikeouts in the second game of a doubleheader against Philadelphia on June 7, limiting the Phillies to five hits in a 2–0 shutout victory. In the first half of the season, he enjoyed a 9–3 record and a 3.05 ERA. He was named to both National League All-Star teams in 1959 (in those days, two All-Star games were played in a season). However, he did not appear in either game. The second half of the season saw him post a 4–7 record and a 5.94 ERA. On July 19, 1959, Mizell allowed three runs over seven innings to defeat the Braves, 9–5.
Sources: en.wikipedia.org
== Mechanism == Rather than being classified as an "autoimmune" disease, SJIA is thought to be an autoinflammatory condition. This is due to the lack of evidence linking any particular antigen-antibody dyad to the pathogenesis or etiology of sJIA. Additionally, sJIA presents with fevers, rash, and multisystem involvement, just like other autoinflammatory illnesses. Autoimmune diseases are adaptive immune system disorders with autoantibodies, while autoinflammatory diseases are caused by innate immune system dysfunction. Several studies show that the innate immune system has a role in sJIA pathogenesis by producing pro-inflammatory cytokines such as interleukin-1, interleukin-6, interleukin-7, interleukin-8, interleukin-18, macrophage migration inhibitory factor, and tumor necrosis factor (TNF). Cytokines have a strong correlation with disease-related systemic characteristics. Elevated interleukin-6 levels are associated with anemia, thrombocytosis, osteoporosis, and delayed growth. Interleukin-1b also contributes significantly to disease etiology.
=== Generic names === Estradiol cypionate is the generic name of the drug and its INNTooltip International Nonproprietary Name and USANTooltip United States Adopted Name. It is also known as estradiol cyclopentylpropionate (ECP).
When multiple copies of a polypeptide encoded by a gene form an aggregate, this protein structure is referred to as a multimer. When a multimer is formed from polypeptides produced by two different mutant alleles of a particular gene, the mixed multimer may exhibit greater functional activity than the unmixed multimers formed by each of the mutants alone. In such a case, the phenomenon is referred to as intragenic complementation. E. coli alkaline phosphatase, a dimer enzyme, exhibits intragenic complementation. By changing the amino acids of the wild-type alkaline phosphatase enzyme produced by Escherichia coli, a mutant alkaline phosphatase is created which not only has a 36-fold increase in enzyme activity, but also retains thermal stability. Typical uses in the lab for alkaline phosphatases include removing phosphate monoesters to prevent self-ligation, which is undesirable during plasmid DNA cloning. Common alkaline phosphatases used in research include:
Because even the longest-lived isotope of technetium has a relatively short half-life (4.21 million years), the 1952 detection of technetium in red giants helped to prove that stars can produce heavier elements.
Insulin degludec/insulin aspart, sold under the brand name Ryzodeg, is a fixed-dose combination medication for the treatment of diabetes mellitus. It contains insulin degludec and insulin aspart. It is given as an injection under the skin in the abdominal wall (at the front of the waist), upper arm or thigh. The most frequently reported side effect is hypoglycemia (low blood glucose levels). It was approved for medical use in the European Union in January 2013, and in Australia in November 2017.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.